Immunome reports Q1 2023 net loss of $4.3M; posts $2.4M collaboration revenue from AbbVie deal

Immunome Inc.

2023-Q1 EPS reported -$0.35 revenue$2,364,000

Collaboration revenue of $2.4M from AbbVie strategic deal for up to 10 novel antibody-target pairs.
Net loss of $4.3M for Q1 2023; R&D expenses $3.9M, G&A expenses $2.8M.
Cash and cash equivalents $44.4M as of March 31, 2023.
AbbVie deal includes $30M upfront, $70M platform milestones, and up to $120M per target in development/commercial milestones.
Formed Antibody-Drug Conjugate and T Cell Redirection Advisory Board in February 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Immunome Inc. reported the first quarter ended March 31, 2023 results: revenue $2.4 million, net income $4.3 million.

Period: the first quarter ended March 31, 2023
Revenue: $2.4 million
Net income: $4.3 million
Result: reported results

Exact text from the filing

including ADCs. Financial Highlights · Collaboration Revenue : Collaboration Revenue from the Collaboration Agreement with AbbVie for the three months ended March 31, 2023 was $2.4 million. · Research and development (R&D) expenses: R&D expenses for the three months ended March 31, 2023 were $3.9 million. · General and administrative (G&A) expenses: G&A expenses,

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

Immunome Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-056320

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.